VANCOUVER, British Columbia / Apr 03, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended 2023 and provided a corporate update.... Read More

VANCOUVER, British Columbia / Mar 20, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it will present at the Emerging Growth Conference on April 3, 2024. The company invites individual and institutional investors as well as advisors and analysts, to attend its real-time,... Read More

VANCOUVER, British Columbia / Feb 22, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it has filed a new composition-of-matter patent that secures broad protection for its lead asset, ALPHA-1062, currently under review by the... Read More

VANCOUVER, British Columbia / Feb 12, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders provides a business update on it’s ALPHA-1062 NDA filing for U.S. approval of mild-to-moderate Alzheimer’s disease, commercialization strategy, and a pipeline update. The Company completed a transformational year as... Read More

VANCOUVER, British Columbia / Jan 19, 2024 / Business Wire / Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has completed a final closing pursuant to its previously announced private placement of units of the Company. Pursuant to the final closing, the Company issued 16,965,762 units of the Company at a price of US$0.22 per unit for gross proceeds of US$3,732,467.... Read More

VANCOUVER, British Columbia / Dec 22, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has completed a fourth closing pursuant to its previously announced private placement of units of the Company. Pursuant to the fourth closing, the Company issued 9,141,534 units of the Company at a price of US$0.22 per unit for gross proceeds of US$2,011,138.... Read More

VANCOUVER, British Columbia / Dec 07, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that the U.S. Food and Drug Administration (FDA) has completed its filing review and has accepted the company’s New Drug Application (NDA) for... Read More

VANCOUVER, British Columbia / Dec 04, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has amended the terms of its previously announced private placement offering of up to US$6.5 million of units at a price of US$0.22 per unit. Each unit will now consist of one common share and one share purchase warrant. Each warrant will entitle the holder to... Read More

VANCOUVER, British Columbia / Nov 28, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the third quarter and nine months ended September 30, 2023, and provided a... Read More

VANCOUVER, British Columbia / Nov 08, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has completed a third closing pursuant to its previously announced private placement of units of the Company. Pursuant to the third closing, the Company issued 4,590,903 units of the Company at a price of US$0.22 per unit for gross proceeds of US$1,009,999.... Read More

VANCOUVER, British Columbia / Sep 27, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ALPHA-1062, a proprietary, patented, delayed... Read More

VANCOUVER, British Columbia / Aug 31, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”) announces the closing of its previously announced private placement of units of the Company for gross proceeds of US$1,345,093 before deducting the placement agent’s fees and other offering expenses payable by the Company. Pursuant to the closing, the Company issued a total of... Read More

VANCOUVER, British Columbia / Aug 22, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended June 30, 2023, and provided a... Read More

VANCOUVER, British Columbia / Aug 14, 2023 / Business Wire / Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 17/575,025, titled “Solid Forms... Read More

VANCOUVER, BC / ACCESSWIRE / April 5, 2023 / Alpha Cognition Inc. (TSX-V:ACOG) (OTCQB:ACOGF), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 at 10:30AM (Local Time -PST). Michael McFadden, CEO of Alpha Cognition, will be hosting the presentation and... Read More

VANCOUVER, British Columbia / Mar 08, 2023 / Business Wire / Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a... Read More

VANCOUVER, British Columbia / Mar 06, 2023 / Business Wire / Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“ Alpha Cognition ”, or the “ Company ”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, announces that the Company expects to complete the second tranche of its ongoing private placement offering prior to March 17, 2023. Please see the Company’s February 16,... Read More

VANCOUVER, British Columbia / Feb 16, 2023 / Business Wire / Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“ Alpha Cognition ”, or the “ Company ”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, is pleased to announce that it has closed the first tranche of its previously announced private placement (the “ Offering ”). Pursuant to the Offering, the Company issued... Read More

VANCOUVER, British Columbia / Feb 08, 2023 / Business Wire / Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“ Alpha Cognition ”, or the “ Company ”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce a private placement financing of units for gross proceeds of up to C$6.8 million... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announced today that it has cancelled an aggregate of 4,655,000 incentive stock options with exercise prices ranging from $0.64 CAD to $1.05 CAD. The board of directors... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced that the company's Chief Medical Officer (CMO), Cedric O’Gorman, MD has resigned to pursue other opportunities. The company has undertaken a search for a... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results and provided a corporate update for the second quarter ended June 30, 2022. "The Company released positive topline data from the ALPHA-1062... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from a bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from its pivotal bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces that the European Patent Office has confirmed the patentability of EP3009143 in amended form following an opposition proceeding involving two opponents. The... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the discovery of two GEM combinations, ALPHA-0702 and ALPHA-0802, and positive preclinical data from each candidate therapy. ALPHA-0702 and ALPHA-0802 are Granulin Epithelin Motifs, or GEMs, derived from... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announces the grant of stock options pursuant to its stock option plan to certain directors of the Company to purchase up to an aggregate of 400,000 common shares of the... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2022. "The Company is on track and plans to release data from the ALPHA-1062 pivotal trial during the... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended December 31, 2021. "This past quarter and the year leading up to it has been a transformational... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces the appointment of Don Kalkofen as Chief Financial Officer (CFO) to replace Jeremy Wright. Mr. Wright will continue to assist the Company in a consulting... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce positive preclinical data from their ALPHA-0602 ALS gene therapy program. These data underscore the robust preclinical evidence supporting... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce histology data from their intranasal ALPHA-1062 Traumatic Brain Injury (TBI) program. ALPHA-1062 treatment was neuroprotective, preserving... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is scheduled to participate in the following investor conferences in January 2022: LifeSci Advisors Partners Corporate Access Event, January 5-7 The Company will be... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the resignation of Dr. Fred Sancilio from his role as Director and President of the Company. Dr. Sancilio will continue to work with Alpha Cognition as a... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program. ALPHA-1062 administration significantly, acutely reduced the... Read More

Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the appointment of Cedric O’Gorman, M.D., as the Company’s Chief Medical Officer. Dr. O’Gorman will lead medical, clinical and regulatory functions in support... Read More

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB:ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that it has reported its Third Quarter financial results of fiscal 2021. Select Financial Information for Q3-2021: (for the period ended September 30,... Read More